Two Sigma Ventures

Two Sigma Ventures Research Investment Thesis Two Sigma Ventures is the venture capital arm of Two Sigma Investments, LP, a $60B+ quantitative hedge fund and financial sciences company. Founded in 2011, the firm invests with the conviction that as the world becomes increasingly information-rich, transformative new companies will leverage data science, machine learning, and advanced computing power to create breakthrough solutions. The firm believes that the intersection of rigorous data analysis and technological innovation unlocks human potential across industries. The fund brings institutional-grade expertise from its parent company, including over 250 PhDs, deep machine learning capability, advanced data infrastructure knowledge, and quantitative modeling expertise. This technical depth differentiates TSV from traditional VCs and allows it to provide hands-on support to portfolio companies in data science, software engineering, and product development. Investment Focus Areas Two Sigma Ventures invests across a broad range of sectors and industries, with particular strength in data-driven and computing-intensive businesses: Core Sectors: Enterprise Software & SaaS Financial Technology (fintech) Techbio & Life Sciences (AI-driven drug discovery, data-rich biology) Healthcare Technology Consumer Technology Web3 & Crypto (approximately 15% of portfolio allocation) Developer Tools & Infrastructure Security & Cybersecurity Real Estate Technology (PropTech) Insurance Technology AI/ML Infrastructure Geographic Presence: Headquartered in New York with offices in London, Tokyo, Hong Kong, Shanghai, Houston, Chicago, and Palm Beach Gardens. Primarily invests in US-based companies with selective international opportunities. Stage Focus & Check Size Two Sigma Ventures focuses on early to growth-stage investments: Stage Preferences: Seed to Series B, with particular emphasis on Seed and Series A investments. The fund occasionally provides pre-seed capital to exceptional founders with compelling visions. Check Size Range: Seed: $2M-$8M Series A: $5M-$15M Growth (Series B): $10M-$25M+ The firm aims to be a long-term partner, often providing follow-on capital to successful portfolio companies. Recent Fund Activity In September 2022, Two Sigma Ventures announced the closing of two new funds totaling $400M in commitments: Two Sigma Ventures IV (TSV IV): Focused on early-stage investments across the firm's core sectors. This fund continued the firm's disciplined approach to Seed and Series A rounds. Two Sigma Ventures Opportunity Fund II (TSV Opps II): Dedicated to growth-stage investments in companies with demonstrated product-market fit and clear scaling trajectories. Fund Composition: Approximately 85% of capital came from external institutional investors (university endowments, non-profit foundations, pension funds, hospital systems), with the remaining 15% from Two Sigma's partners and senior employees, demonstrating significant founder commitment. Current Deployment Status: The firm is actively deploying capital from these funds, with recent investments in 2025 including Bedrock Robotics (Series A, July 2025) and NetBox Labs (Series B, June 2025). Portfolio & Investment Style Two Sigma Ventures has built a diverse portfolio of 100+ companies across its investment history since 2011. Notable portfolio companies include: High-Profile Exits & Success Stories: Recursion Pharmaceuticals (AI-driven drug discovery, now public) WHOOP (wearable health technology) Zymergen (biotechnology) GitLab (DevOps platform, now public) Remote (distributed workforce management) Active Portfolio Highlights: insitro (AI-powered drug discovery) Enigma (data intelligence platform) Kasisto (conversational AI banking) Carbon Health (modern healthcare delivery) CoverWallet (insurance management SaaS) Placement (location intelligence) Pro.com (home services marketplace) Kallyope (synthetic biology) Hexagon Bio (gene synthesis) Terray Therapeutics (AI-powered drug discovery) Notable Characteristics of Portfolio: Strong representation in techbio/biotech (data-rich life sciences) Enterprise software with data science moats Infrastructure and developer tools leveraging AI/ML Consumer companies with proprietary data advantages Crypto/Web3 projects with fundamental data infrastructure angles Team & Expertise Core Investment Team (Partners): Colin Beirne, Partner: Former banker and strategist at Two Sigma since 2005. Launched TSV in 2011. Focuses on fintech, enterprise AI, robotics, and retail tech. Leads the overall fund strategy. Dusan Perovic, Partner: Directs investing at the intersection of life sciences/healthcare and data science. Former healthcare consultant with deep biotech expertise. Princeton engineering graduate. Dan Abelon, Partner Sidney Costabile, Partner Frances Schwiep, Partner Joe Botsch, Principal: Senior analyst supporting investment thesis research and due diligence. Supporting Team: Patrick McCarthy, Director - Applied Data Research: Leads quantitative research backing investment decisions Tyler Mann, Head of Legal Riz Thakir, Vice President - Finance Elianna Knight & Rohit Rao, Investors Additional team of 15+ professionals in operations, legal, marketing, and administrative roles Venture Partners & Advisors: Villi Iltchev, Venture Partner (formerly Partner) Michael Abbott, Advisor Matt Jacobus, Venture Partner Boris Sofman, Advisor Ann Ruble, Advisor Marc Weill, Venture Partner Claudia Perlich, Advisor (data science expert) Matt Greenwood, Advisor Jeff Wecker, Advisor Value-Add Beyond Capital Two Sigma Ventures distinguishes itself through five core support pillars: 1. People Operations: Talent network with 40,000+ vetted technical candidates from Two Sigma's applicant pool Peer communities connecting portfolio founders Compensation benchmarking across 4,000+ global startups Manager training programs for executive development 2. Customer Engagement: Access to 35,000+ decision makers at 16,000+ organizations Introductions to corporate partners for customers, pilots, and strategic relationships Industry roundtables for B2B sales strategy Sales process navigation support 3. Data Science Support: Hands-on data deep dives with Two Sigma technologists Model review and optimization from world-class data scientists Data infrastructure guidance (storage, processing, management) Access to proprietary datasets and analytical frameworks 4. Product & Engineering: Architecture audits from senior Two Sigma engineers Cloud infrastructure optimization and management Security review and hardening (critical for regulated businesses) Women in tech roundtables and diversity initiatives 5. Marketing & Communications: Go-to-market strategy and launch planning Press support and PR strategy Editorial content templates and comms planning Coverage in tier-1 publications (NY Times, Reuters, Business Insider connections) Decision Process & Timeline Decision Structure: Partnership-based decision making with consensus among core partners. Key deals typically involve Colin Beirne (overall strategy), Dusan Perovic (for biotech/healthcare), and relevant partner specialists. Investment Timeline: Standard VC velocity - typically 4-8 weeks from introduction to term sheet for aligned opportunities. Due diligence depth varies by sector (biotech receives extensive scientific review via partner network). Warm Introductions: Strongly preferred, though inbound referrals from portfolio companies and trusted sources are considered. Lead vs Follow Tendency Lead Tendency: LEADS - Two Sigma Ventures is an active lead investor in early rounds. The firm's conviction in its data-science thesis and deep technical expertise allow it to size checks confidently and drive term sheets. In growth rounds (Series B+), the firm may co-lead or follow depending on the quality of the lead syndicate and fit with portfolio thesis. Anti-Thesis & Founder Preferences Who They Back: Founders with deep technical expertise (especially data science, ML, biology, engineering) Founders with shipping track records and domain depth Teams that benefit from access to Two Sigma's technical infrastructure Businesses with defensible data advantages or AI/ML moats CEOs capable of building world-class engineering cultures Who They Don't Back: Pure consumer consumer app plays without data/computing angles Services-based businesses (low tech leverage) Hardware without significant software/AI components Businesses requiring pharmaceutical regulatory expertise beyond data science Teams lacking technical founders or deep domain expertise Values & Culture Two Sigma Ventures operates according to four core institutional values: SMARTER TOGETHER: Belief in collective intelligence and augmentation of capabilities through networks and collaboration HUMBLY OPEN-MINDED: Acknowledgment of uncertainty with commitment to rigorous learning and discovery EMPATHETIC: Deep understanding of founder challenges and long-term partnership approach CHALLENGING CONVENTION: Commitment to technological innovation and disruption of status quo Recent Notable Investments (2025) Bedrock Robotics (Series A, July 2025) NetBox Labs (Series B, June 2025) Multiple investments across biotech, enterprise software, and infrastructure Competitive Position Two Sigma Ventures occupies a unique position in VC: One of the few true "data science VCs" with institutional expertise Significant technical depth (250+ PhDs in parent company) Patient capital with long-term partnership orientation Non-consensus views on sectors like Web3 (15% allocation while others retreated) Strong brand in biotech and enterprise software circles Main competitors: Khosla Ventures, Bessemer Venture Partners, Sequoia Capital's Data Science focused efforts, Greylock Partners, Canaan Partners, and specialized biotech VCs like Lowercarbon Capital. Fundraising & Commitment to Market The September 2022 fund close with $400M demonstrates strong institutional support and confidence in the firm's data-science thesis. The external capital percentage (85%) indicates that the best university endowments, pension funds, and foundations trust Two Sigma Ventures' approach. The firm's decade-long track record (100+ companies since 2011) and focus on data-driven sectors positions it well for continued institutional LP support. Geographic & Sector Appetite Geographic: US-centric (NYC, SF Bay Area, Boston) with selective expansion in Europe (London) and Asia (Tokyo, Hong Kong, Shanghai) for specific sector opportunities (biotech, finance tech). Sector Appetite (High to Low): Biotech & Life Sciences (data-rich biology, AI drug discovery) - VERY HIGH Enterprise Software (especially data-intensive) - HIGH Fintech (leveraging quantitative expertise) - HIGH Developer Tools & Infrastructure - HIGH Security & Cybersecurity - MEDIUM-HIGH Consumer Tech (with data moats) - MEDIUM Web3/Crypto (selective, ~15% of portfolio) - MEDIUM PropTech & Real Estate Tech - MEDIUM Healthcare Tech (non-biotech) - MEDIUM Insurance Tech - MEDIUM